SCHEMBL23456281

SCHEMBL23456281

C[C@H]1CN(C(=O)O)CCN1C(=O)c1ccc(O[C@H]2CCN(C(=O)OC(C)(C)C)C2)c(-c2ccc(F)cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ SETD7 Q8WTS6 2/20 0.49
▸ GHSR Q92847 3/20 0.46
▸ BCL9 O00512 12/20 0.44
▸ CTNNB1 P35222 12/20 0.44
▸ PIK3CD O00329 2/20 0.41
▸ PIK3CA P42336 2/20 0.41
▸ PIK3CB P42338 2/20 0.41
▸ PIK3CG P48736 2/20 0.41
▸ ROCK2 O75116 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23456282 1.00 SETD7 (0.49) SETD7GHSRBCL9CTNNB1PIK3CD
SCHEMBL23456174 0.90 BCL9 (0.51) BCL9CTNNB1PIK3CDPIK3CAPIK3CB
SCHEMBL23456173 0.90 BCL9 (0.51) BCL9CTNNB1PIK3CDPIK3CAPIK3CB
SCHEMBL23456150 0.90 BCL9 (0.55) BCL9CTNNB1PIK3CDPIK3CAPIK3CB
SCHEMBL23456284 0.90 BCL9 (0.55) BCL9CTNNB1PIK3CDPIK3CAPIK3CB
SCHEMBL23456285 0.90 BCL9 (0.55) BCL9CTNNB1PIK3CDPIK3CAPIK3CB
SCHEMBL23456146 0.90 BCL9 (0.55) BCL9CTNNB1PIK3CDPIK3CAPIK3CB
SCHEMBL30171240 0.90 SETD7 (0.44) SETD7GHSRBCL9CTNNB1ROCK2
SCHEMBL30392250 0.87 BCL9 (0.51) BCL9CTNNB1
SCHEMBL23456242 0.86 BCL9 (0.62) BCL9CTNNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230122912-A1 Methods and Compositions of 4-Substituted Benzoylpiperazine-1-Substituted Carbonyls as Beta-Catenin/B-Cell Lymphoma 9 Imhibitors UNIVERSITY OF UTAH RESEARCH FOUNDATION 2023-04-20 — — US disclosed
US-11542254-B2 Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors UNIVERSISITY OF UTAH RESEARCH FOUNDATION (US) 2023-01-03 — — US disclosed
US-20210171502-A1 METHODS AND COMPOSITION OF 4-SUBSTITUTED BENZOYLPIPERAZINE-1-SUBSTITUTED CARBONYLS AS BETA-CATENIN/B-CELL LYMPHOMA 9 INHIBITORS UNITED STATES GOVERNMENT 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171502-A1 METHODS AND COMPOSITION OF 4-SUBSTITUTED BENZOYLPIPERAZINE-1-SUBSTITUTED CARBONYLS AS BETA-CATENIN/B-CELL LYMPHOMA 9 INHIBITORS BCL9, BCL9L, BCL3 SETD7 928/4885GHSR 4162/4885BCL9 1/4885
US-11542254-B2 Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors BCL9, BCL9L, BCL3 SETD7 886/4885GHSR 4036/4885BCL9 1/4885
US-20230122912-A1 Methods and Compositions of 4-Substituted Benzoylpiperazine-1-Substituted Carbonyls as Beta-Catenin/B-Cell Lymphoma 9 Imhibitors BCL9, BCL9L, BCL3 SETD7 1713/4885GHSR 3788/4885BCL9 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback